Clinical trials · New York
Advanced Cancer clinical trials in New York
We’re tracking 272 recruiting advanced cancer studies with a site in New York — including Phase 1, Phase 1/Phase 2, Phase 2 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies in New York
- NCT05824975RecruitingPhase 1/Phase 2
Test drug GI-102 alone or with cancer medicines
This Phase 1/2 study tests whether GI-102 is safe and can help shrink advanced solid tumors. It also looks at GI-102 used with standard cancer treatments like pembrolizumab or trastuzumab deruxtecan (T-DXd).
New York, New YorkAges 18 years+ - NCT06793215RecruitingPhase 3
Divarasib plus pembrolizumab for KRAS G12C lung cancer
This trial compares a new targeted drug (divarasib) combined with an immunotherapy (pembrolizumab) versus standard chemotherapy plus immunotherapy for people with advanced lung cancer that has a specific KRAS G12C mutation. It aims to see if the new combination works better and is safe.
Syracuse, New YorkAges 18 years+ - NCT05589818RecruitingPhase 2
Pembrolizumab for advanced lung cancer without key gene targets
This Phase 2 trial studies pembrolizumab (an immunotherapy drug) in people with advanced non-small cell lung cancer whose disease can’t be treated with curative surgery or combined chemoradiation. It aims to see how well the treatment works and how safely it can be given, especially for people who have not had other cancer medicines for metastatic disease.
New York, New YorkAges 18 years+ - NCT06655246RecruitingPhase 1
Ziftomenib and imatinib for advanced GIST
This trial tests a new drug, ziftomenib, combined with imatinib for people with advanced or spreading gastrointestinal stromal tumors (GIST) that have a KIT mutation. It may help if your GIST has gotten worse while on imatinib.
New York, New YorkAges 18 years+ - NCT07431281RecruitingPhase 3
New drug combo for advanced stomach cancer with CLDN18.2
This trial tests a new drug combination for people with advanced stomach cancer that has not been treated before. It looks at two groups: one with PD-L1 (a protein that helps decide if immunotherapy works), and one without. The treatment includes an antibody-drug conjugate (Sonesitatug Vedotin) plus standard chemotherapy, with or without an immunotherapy drug.
White Plains, New YorkAges 18 years+ - NCT06905197RecruitingPhase 1
Study of DZD6008 for advanced NSCLC with EGFR mutations
This trial tests an oral drug called DZD6008 for people with advanced non-small cell lung cancer (NSCLC) that has certain EGFR mutations. It may be an option for those who have tried other EGFR treatments or are new to treatment.
New York, New YorkAges 18 years+ - NCT07164313RecruitingPhase 1
ZW251 for advanced solid tumors
This trial is testing a new drug called ZW251 for people with advanced liver cancer (hepatocellular carcinoma), non-small cell lung cancer, or germ cell tumors that have spread or cannot be removed by surgery. It aims to see if the drug is safe and effective.
New York, New YorkAges 18 years+ - NCT06778863RecruitingPhase 1
A study of CLSP-1025 for adults with certain solid tumors
This trial tests a new drug called CLSP-1025 for people with advanced solid tumors that have a specific change in the p53 gene (R175H). The drug targets this change to help fight the cancer.
New York, New YorkAges 18 years+ - NCT05677490RecruitingPhase 3
Chemo options, with or without nivolumab, for HER2-negative stomach cancer
This Phase 3 trial compares two standard chemotherapy regimens for advanced stomach, esophagus, or gastroesophageal junction cancer that is HER2-negative. It also tests whether adding nivolumab (an immune therapy) improves outcomes.
Brooklyn, New YorkAges 18 years+ - NCT04683250RecruitingPhase 1/Phase 2
RET-targeting drug study for advanced cancers with RET changes
This trial tests an “RET-inhibitor” medicine (TAS0953/HM06) for advanced solid tumors that have RET gene changes. It may help shrink tumors by blocking cancer growth signals from the RET gene.
New York, New YorkAges 18 years+ - NCT04198766RecruitingPhase 1/Phase 2
New OX40 immunotherapy for advanced solid tumors
This trial tests a new immunotherapy drug (INBRX-106) alone or with Keytruda (pembrolizumab) for adults with advanced solid tumors that have not responded to standard treatments. The goal is to see if the drug can help the immune system fight cancer.
The Bronx, New YorkAges 18 years+ - NCT06469944RecruitingPhase 1/Phase 2
Study of drug combinations for stomach or esophagus cancer
This trial tests new combinations of drugs alongside standard chemotherapy for people with advanced stomach or esophagus cancer that has not been treated yet. It aims to see if these combinations can shrink tumors or slow down the cancer better than current options.
East Syracuse, New YorkAges 18 years+ - NCT06627647RecruitingPhase 3
Comparing two immunotherapy drugs for advanced lung cancer
This trial tests a new immunotherapy drug, rilvegostomig, against the standard pembrolizumab, both given with chemotherapy, as a first treatment for advanced non-squamous non-small cell lung cancer (NSCLC) that cannot be cured with surgery or radiation. It is for people whose tumors have high PD-L1 levels and do not have certain genetic mutations.
Buffalo, New YorkAges 18 years+ - NCT06917079RecruitingPhase 1
BBO-11818 for KRAS-mutated cancers
This trial tests a new oral drug (BBO-11818) for people with solid tumors that have a specific KRAS mutation. It's for those whose cancer has spread or cannot be removed by surgery and who have not had other cancers recently.
New York, New YorkAges 18 years+ - NCT07100106RecruitingPhase 1/Phase 2
Study of GDC-4198 alone or with giredestrant for advanced breast cancer
This trial tests a new treatment (GDC-4198) alone or with another drug (giredestrant) compared to a standard combination (abemaciclib and giredestrant) for people with advanced hormone receptor-positive, HER2-negative breast cancer that has progressed after previous treatments.
East Patchogue, New YorkAges 18 years+ - NCT04429542RecruitingPhase 1
Test of an EGFR-targeting drug for advanced solid cancers
This Phase 1 study tests the safety of BCA101 (an EGFR-targeting treatment) alone or combined with pembrolizumab. It may help people with certain EGFR-driven advanced cancers, depending on the tumor type, prior treatments, and required biopsy testing.
New York, New YorkAges 18 years+ - NCT07291037RecruitingPhase 3
Study of datopotamab deruxtecan vs docetaxel for advanced lung cancer
This trial tests a new drug, datopotamab deruxtecan, against a standard chemotherapy (docetaxel) for people with advanced non-squamous lung cancer that has gotten worse after previous treatment. It is for those who do not have certain genetic changes (like EGFR, ALK, or ROS1) and whose tumors have a protein called TROP2.
East Syracuse, New YorkAges 18 years+ - NCT05498428RecruitingPhase 2
Amivantamab for advanced lung cancer with EGFR mutations
This Phase 2 study tests amivantamab (an antibody medicine) in people with advanced or metastatic non-small cell lung cancer that has specific EGFR gene changes. It may help shrink tumors or control cancer when standard curative treatments aren’t possible.
East Syracuse, New YorkAges 18 years+ - NCT06413680RecruitingPhase 1/Phase 2
Study of REGN10597 with or without cemiplimab for advanced solid tumors
This study tests a new drug called REGN10597, either alone or with cemiplimab, for people with advanced solid tumors (like melanoma or kidney cancer) that have not responded to standard treatments. The goal is to see if the combination can shrink tumors or slow their growth.
Lake Success, New YorkAges 18 years+ - NCT05172245RecruitingPhase 1
Testing a new drug added to chemoradiation for head and neck cancer
This study tests whether adding a new targeted drug called ipatasertib to standard chemoradiation can improve treatment for people with locally advanced head and neck cancer. Ipatasertib may help block a protein that helps cancer grow, possibly making the standard therapy more effective.
The Bronx, New YorkAges 18 years+ - NCT04104776RecruitingPhase 1/Phase 2
Test drug tulmimetostat for advanced cancers and lymphomas
This early-phase study tests tulmimetostat (DZR123) to shrink or control advanced solid tumors and certain lymphomas, and it may also test a combination in some prostate cancer groups. If you qualify, you’ll receive the study drug and be monitored closely, including blood tests and a request for tumor tissue to look for biomarkers.
Buffalo, New YorkAges 18 years+ - NCT05877599RecruitingPhase 1
Study of a new treatment for advanced cancers with a specific gene change
This trial tests a new type of therapy (NT-175) for people with certain advanced cancers that have a specific genetic change. It might help if your tumor has the TP53 R175H mutation and you have the HLA-A*02:01 immune marker.
New York, New YorkAges 18 years+ - NCT04577014RecruitingPhase 1/Phase 2
Retifanlimab plus chemotherapy for advanced soft tissue sarcoma
This trial tests retifanlimab (an immunotherapy that helps your immune system recognize cancer) combined with gemcitabine and docetaxel chemotherapy. It’s for people with advanced soft tissue sarcoma that can’t be safely removed with surgery, aiming to shrink tumors and improve outcomes.
New York, New YorkAges 18 years+ - NCT06357533RecruitingPhase 3
New drug combo for advanced lung cancer with high PD-L1
This trial tests a new two-drug combination (Dato-DXd and an immunotherapy called rilvegostomig) as the first treatment for people with advanced non-squamous lung cancer who have high PD-L1 levels. The goal is to see if this combination works better than current standard options.
Stony Brook, New YorkAges 18 years+
Advanced Cancer trials by city in New York
Where these studies are running in New York
Institutions with a site for the recruiting advanced cancer studies listed above.
- Memorial Sloan Kettering Cancer Center · 8 studies
- NYU Langone Health · 5 studies
- Research Site · 5 studies
- Montefiore Medical Center · 4 studies
- Columbia University Irving Medical Center · 3 studies
- Columbia University Herbert Irving Comprehensive Cancer Center · 2 studies
- Hematology Oncology Associates of Central New York · 2 studies
- Montefiore Einstein Comprehensive Cancer Center · 2 studies
What taking part in a advanced cancer study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Advanced Cancer trials in other states
Common questions
- Are there advanced cancer clinical trials in New York?
- Yes. We're currently tracking 272 recruiting advanced cancer studies with a site in New York, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a advanced cancer study in New York?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in New York to take part?
- Not necessarily. These studies have a site in New York, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a advanced cancer trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New advanced cancer studies open in New York regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.